Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)
Randomizovaná, dvojitě zaslepená, dvojitě falešná studie s paralelními skupinami, porovnávající účinnost a bezpečnost remibrutinibu versus teriflunomid u účastníků s recidivující roztroušenou sklerózou, po níž následovala rozšířená léčba remibrutinibem
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Detailní popis
The study CLOU064C12302 consists of an initial Core Part (CP) (maximum duration per participant of up to 30 months), followed by an Extension Part (EP, of up to 5 years duration) for eligible participants.
The Core Part is a randomized, double-blind, double-dummy, active comparator-controlled, fixed-dose, parallel-group, multi-center study in approximately 800 participants with relapsing multiple sclerosis (RMS).
The Extension Part is an open-label, single-arm, fixed-dose design in which eligible participants are treated with remibrutinib for up to 5 years.
A second study of identical design (CLOU064C12301) will be conducted simultaneously. Both studies will be conducted globally and data from the two studies will be pooled for some of the endpoints.
Typ studie
Typ studie
Zápis (Aktuální)
Zápis
Fáze
Fáze
- Fáze 3
Kontakty a umístění
Studijní místa
-
-
-
Buenos Aires, Argentina, C1012AAR
- Novartis Investigative Site
-
CABA, Argentina, C1181ACH
- Novartis Investigative Site
-
Córdoba, Argentina, X5004CDT
- Novartis Investigative Site
-
-
Mendoza Province
-
Bombal, Mendoza Province, Argentina, M5500DXO
- Novartis Investigative Site
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentina, S2000BZL
- Novartis Investigative Site
-
Rosario, Santa Fe Province, Argentina, S2000DSW
- Novartis Investigative Site
-
-
Tucumán Province
-
San Miguel de, Tucumán Province, Argentina, T4000
- Novartis Investigative Site
-
-
-
-
-
São Paulo, Brazílie, 01240-020
- Novartis Investigative Site
-
-
Espírito Santo
-
Vitória, Espírito Santo, Brazílie, 29055-450
- Novartis Investigative Site
-
-
Federal District
-
Brasília, Federal District, Brazílie, 70200-730
- Novartis Investigative Site
-
-
Paraná
-
Curitiba, Paraná, Brazílie, 81210-310
- Novartis Investigative Site
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brazílie, 90430-001
- Novartis Investigative Site
-
Porto Alegre, Rio Grande do Sul, Brazílie, 90560-032
- Novartis Investigative Site
-
Porto Alegre, Rio Grande do Sul, Brazílie, 90620-130
- Novartis Investigative Site
-
-
Santa Catarina
-
Joinville, Santa Catarina, Brazílie, 89202-165
- Novartis Investigative Site
-
-
-
-
-
Plovdiv, Bulharsko, 4002
- Novartis Investigative Site
-
Sofia, Bulharsko, 1309
- Novartis Investigative Site
-
Sofia, Bulharsko, 1431
- Novartis Investigative Site
-
Sofia, Bulharsko, 1407
- Novartis Investigative Site
-
-
-
-
-
Zagreb, Chorvatsko, 10000
- Novartis Investigative Site
-
-
Croatia
-
Zagreb, Croatia, Chorvatsko, 10000
- Novartis Investigative Site
-
-
HRV
-
Split, HRV, Chorvatsko, 21000
- Novartis Investigative Site
-
Varaždin, HRV, Chorvatsko, 42000
- Novartis Investigative Site
-
-
Vukovar
-
Vukovar, Vukovar, Chorvatsko, 32000
- Novartis Investigative Site
-
-
-
-
-
Tallinn, Estonsko, 11315
- Novartis Investigative Site
-
Tartu, Estonsko, 50406
- Novartis Investigative Site
-
-
-
-
-
Caen, Francie, 14033
- Novartis Investigative Site
-
Clermont-Ferrand, Francie, 63003
- Novartis Investigative Site
-
Dijon, Francie, 21000
- Novartis Investigative Site
-
Gonesse, Francie, 95500
- Novartis Investigative Site
-
Grenoble, Francie, 38043
- Novartis Investigative Site
-
Lille, Francie, 59037
- Novartis Investigative Site
-
Lille, Francie, 59000
- Novartis Investigative Site
-
Nice, Francie, 06000
- Novartis Investigative Site
-
Nîmes, Francie, 30029
- Novartis Investigative Site
-
Poissy, Francie, 78303
- Novartis Investigative Site
-
Toulouse, Francie, 31059
- Novartis Investigative Site
-
-
Haute Vienne
-
Limoges, Haute Vienne, Francie, 87000
- Novartis Investigative Site
-
-
Val De Marne
-
Toulon, Val De Marne, Francie, 83800
- Novartis Investigative Site
-
-
-
-
Kerala
-
Kochi, Kerala, Indie, 682025
- Novartis Investigative Site
-
-
Maharashtra
-
Pune, Maharashtra, Indie, 411013
- Novartis Investigative Site
-
-
National Capital Territory of Delhi
-
New Delhi, National Capital Territory of Delhi, Indie, 110060
- Novartis Investigative Site
-
-
Punjab
-
Amritsar, Punjab, Indie, 143006
- Novartis Investigative Site
-
-
Telangana
-
Hyderabad, Telangana, Indie, 500082
- Novartis Investigative Site
-
-
Uttar Pradesh
-
Lucknow, Uttar Pradesh, Indie, 226007
- Novartis Investigative Site
-
-
West Bengal
-
Kolkata, West Bengal, Indie, 700017
- Novartis Investigative Site
-
-
-
-
-
Naples, Itálie, 80138
- Novartis Investigative Site
-
-
BR
-
Brindisi, BR, Itálie, 72100
- Novartis Investigative Site
-
-
FG
-
Foggia, FG, Itálie, 71122
- Novartis Investigative Site
-
-
IS
-
Pozzilli, IS, Itálie, 86077
- Novartis Investigative Site
-
-
ME
-
Messina, ME, Itálie, 98124
- Novartis Investigative Site
-
-
MO
-
Modena, MO, Itálie, 41126
- Novartis Investigative Site
-
-
PV
-
Pavia, PV, Itálie, 27100
- Novartis Investigative Site
-
-
TO
-
Orbassano, TO, Itálie, 10043
- Novartis Investigative Site
-
-
-
-
-
Fukuoka, Japonsko, 8128582
- Novartis Investigative Site
-
Niigata, Japonsko, 9518520
- Novartis Investigative Site
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japonsko, 4668560
- Novartis Investigative Site
-
-
Chiba
-
Chiba, Chiba, Japonsko, 2608677
- Novartis Investigative Site
-
Ichihara, Chiba, Japonsko, 2990111
- Novartis Investigative Site
-
-
Fukuoka
-
Fukuoka, Fukuoka, Japonsko, 8100022
- Novartis Investigative Site
-
-
Hokkaido
-
Sapporo, Hokkaido, Japonsko, 0630005
- Novartis Investigative Site
-
-
Hyōgo
-
Kobe, Hyōgo, Japonsko, 6500017
- Novartis Investigative Site
-
Nishinomiya, Hyōgo, Japonsko, 663 8501
- Novartis Investigative Site
-
-
Kanagawa
-
Isehara, Kanagawa, Japonsko, 2591193
- Novartis Investigative Site
-
Sagamihara, Kanagawa, Japonsko, 2520375
- Novartis Investigative Site
-
-
Kyoto
-
Kyoto, Kyoto, Japonsko, 6168255
- Novartis Investigative Site
-
-
Miyagi
-
Sendai, Miyagi, Japonsko, 9838512
- Novartis Investigative Site
-
-
Nara
-
Kashihara, Nara, Japonsko, 6348522
- Novartis Investigative Site
-
-
Osaka
-
Moriguchi, Osaka, Japonsko, 5708507
- Novartis Investigative Site
-
Suita, Osaka, Japonsko, 5650871
- Novartis Investigative Site
-
-
Saitama
-
Higashi-Matsuyama, Saitama, Japonsko, 3550005
- Novartis Investigative Site
-
-
Tokyo
-
Kodaira, Tokyo, Japonsko, 1878551
- Novartis Investigative Site
-
Shinjuku Ku, Tokyo, Japonsko, 1628666
- Novartis Investigative Site
-
Shinjuku Ku, Tokyo, Japonsko, 1600023
- Novartis Investigative Site
-
Shinjuku-ku, Tokyo, Japonsko, 1608582
- Novartis Investigative Site
-
tabashi City, Tokyo, Japonsko, 1738610
- Novartis Investigative Site
-
-
-
-
-
Pretoria, Jižní Afrika, 0041
- Novartis Investigative Site
-
Rosebank, Jižní Afrika, 2196
- Novartis Investigative Site
-
-
Free State
-
Bloemfontein, Free State, Jižní Afrika, 9301
- Novartis Investigative Site
-
-
-
-
Alberta
-
Edmonton, Alberta, Kanada, T6G 2B7
- Novartis Investigative Site
-
-
British Columbia
-
Burnaby, British Columbia, Kanada, V5G 2X6
- Novartis Investigative Site
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada, B3H 4K4
- Novartis Investigative Site
-
-
Ontario
-
Ottawa, Ontario, Kanada, K1H 8L6
- Novartis Investigative Site
-
-
Quebec
-
Lévis, Quebec, Kanada, G6W 0M5
- Novartis Investigative Site
-
Montreal, Quebec, Kanada, H4A 3T2
- Novartis Investigative Site
-
Québec, Quebec, Kanada, G1J 1Z4
- Novartis Investigative Site
-
Saint-Jérôme, Quebec, Kanada, J7Z 5T3
- Novartis Investigative Site
-
-
-
-
-
Mexico City, Mexiko, 14050
- Novartis Investigative Site
-
Querétaro, Mexiko, 76070
- Novartis Investigative Site
-
-
Chihuahua
-
Chihuahua City, Chihuahua, Mexiko, 31203
- Novartis Investigative Site
-
-
Mexico City
-
Mexico City, Mexico City, Mexiko, 06700
- Novartis Investigative Site
-
-
-
-
-
Essen, Německo, 45147
- Novartis Investigative Site
-
Hamburg, Německo, 22179
- Novartis Investigative Site
-
-
Baden-Wurttemberg
-
Freiburg im Breisgau, Baden-Wurttemberg, Německo, 79106
- Novartis Investigative Site
-
-
-
-
-
Bialystok, Polsko, 15-704
- Novartis Investigative Site
-
Glogow Wielkopolski, Polsko, 36-060
- Novartis Investigative Site
-
Katowice, Polsko, 40-081
- Novartis Investigative Site
-
Katowice, Polsko, 40-571
- Novartis Investigative Site
-
Katowice, Polsko, 40-686
- Novartis Investigative Site
-
Katowice, Polsko, 40-689
- Novartis Investigative Site
-
Lublin, Polsko, 20-701
- Novartis Investigative Site
-
Wroclaw, Polsko, 51-685
- Novartis Investigative Site
-
Zabrze, Polsko, 41-800
- Novartis Investigative Site
-
-
Poznan
-
Plewiska, Poznan, Polsko, 62-064
- Novartis Investigative Site
-
-
-
-
-
Guaynabo, Portoriko, 00968
- Caribbean Center for Clinical Research Inc
-
-
-
-
-
Braga, Portugalsko, 4710-243
- Novartis Investigative Site
-
Coimbra, Portugalsko, 3004-561
- Novartis Investigative Site
-
Leiria, Portugalsko, 2410-197
- Novartis Investigative Site
-
Lisbon, Portugalsko, 1649-035
- Novartis Investigative Site
-
Lisbon, Portugalsko, 1169-050
- Novartis Investigative Site
-
Matosinhos Municipality, Portugalsko, 4454-513
- Novartis Investigative Site
-
Santa Maria da Feira, Portugalsko, 4520-211
- Novartis Investigative Site
-
-
-
-
-
Campulung Muscel, Rumunsko, 115100
- Novartis Investigative Site
-
Constanța, Rumunsko, 900591
- Novartis Investigative Site
-
-
ROM
-
Brasov, ROM, Rumunsko, 500123
- Novartis Investigative Site
-
Constanța, ROM, Rumunsko, 900123
- Novartis Investigative Site
-
-
-
-
-
Banská Bystrica, Slovensko, 975 17
- Novartis Investigative Site
-
Banská Bystrica, Slovensko, 974 04
- Novartis Investigative Site
-
Bratislava, Slovensko, 833 05
- Novartis Investigative Site
-
-
-
-
-
Celje, Slovinsko, 3000
- Novartis Investigative Site
-
Ljubljana, Slovinsko, 1000
- Novartis Investigative Site
-
-
Slovenia
-
Maribor, Slovenia, Slovinsko, 2000
- Novartis Investigative Site
-
-
-
-
Invernesshire
-
Inverness, Invernesshire, Spojené království, IV2 3RE
- Novartis Investigative Site
-
-
Kent
-
Canterbury, Kent, Spojené království, CT1 3NG
- Novartis Investigative Site
-
-
-
-
Arizona
-
Phoenix, Arizona, Spojené státy, 85018
- Ctr for Neurology and Spine
-
-
California
-
Hanford, California, Spojené státy, 93230
- Vladimir Royter MD APMC
-
Los Angeles, California, Spojené státy, 90073
- VA Greater LA Healthcare System
-
West Hollywood, California, Spojené státy, 90048
- Regina Berkovich MD PhD Inc
-
-
Colorado
-
Aurora, Colorado, Spojené státy, 80045
- CU Anschutz Med Campus
-
Denver, Colorado, Spojené státy, 80210
- Colorado Neurological Research PC
-
-
Connecticut
-
Stamford, Connecticut, Spojené státy, 06905
- New England Institute for Clinical Research
-
-
District of Columbia
-
Washington D.C., District of Columbia, Spojené státy, 20007
- Georgetown University Hospital
-
Washington D.C., District of Columbia, Spojené státy, 20007
- Georgetown University Hospital Research
-
-
Florida
-
Bradenton, Florida, Spojené státy, 34209
- Nova Clinical Research LLC
-
Gainesville, Florida, Spojené státy, 32610
- University of Florida
-
Hollywood, Florida, Spojené státy, 33021
- Memorial Healthcare System
-
Maitland, Florida, Spojené státy, 32751
- Neurology Associates PA
-
Miami, Florida, Spojené státy, 33136
- UM Department Of Neurology
-
Miami, Florida, Spojené státy, 33133
- Gables Neurology
-
Naples, Florida, Spojené státy, 34105
- Aqualane Clinical Research
-
Orlando, Florida, Spojené státy, 32803
- Advent Health Orlando
-
Pembroke Pines, Florida, Spojené státy, 33024
- Humanity Clinical Research
-
Pensacola, Florida, Spojené státy, 32514
- Emerald Coast Neurology
-
Port Orange, Florida, Spojené státy, 32127
- Brain and Spine Institute
-
Vero Beach, Florida, Spojené státy, 32960
- Vero Beach Neurology
-
Winter Park, Florida, Spojené státy, 32789
- Conquest Research
-
-
Indiana
-
Merrillville, Indiana, Spojené státy, 46410
- Methodist Neuroscience Institute
-
-
Kansas
-
Kansas City, Kansas, Spojené státy, 66160
- University of Kansas Hospital
-
-
Kentucky
-
Nicholasville, Kentucky, Spojené státy, 40356
- Baptist Physicians Lexington
-
-
Louisiana
-
New Orleans, Louisiana, Spojené státy, 70121
- Ochsner Clinic Foundation
-
-
Maryland
-
Frederick, Maryland, Spojené státy, 21702
- Clinre Comprehensive Neurology
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02111
- Tufts Medical Center
-
-
Missouri
-
Kansas City, Missouri, Spojené státy, 64128
- Kansas City VA Medical Center
-
-
New York
-
Patchogue, New York, Spojené státy, 11772
- South Shore Neurologic Associates
-
-
North Carolina
-
Chapel Hill, North Carolina, Spojené státy, 27599-9500
- University Of NC At Chapel Hill
-
Charlotte, North Carolina, Spojené státy, 28210
- Piedmont HealthCare
-
-
Ohio
-
Columbus, Ohio, Spojené státy, 43235
- The Boster Ctr for MS
-
Dayton, Ohio, Spojené státy, 45408
- Neurology Diagnostics Inc
-
-
Pennsylvania
-
Hershey, Pennsylvania, Spojené státy, 17033
- Penn State Hershey Medical Center
-
-
South Carolina
-
Greenville, South Carolina, Spojené státy, 29605
- Premier Neurology
-
Old Point Station, South Carolina, Spojené státy, 29707
- Metrolina Neurological Associates PA
-
-
Tennessee
-
Knoxville, Tennessee, Spojené státy, 37922
- Sibyl Wray MD Neurology PC
-
-
Texas
-
Dallas, Texas, Spojené státy, 75231
- Carum Research
-
El Paso, Texas, Spojené státy, 79935
- Med Research Inc
-
Frisco, Texas, Spojené státy, 75035
- Lone Star Neurology
-
San Antonio, Texas, Spojené státy, 78258
- Lonestar Neurology of San Antonio
-
San Antonio, Texas, Spojené státy, 78229
- UT Health MARC Medical Arts and Research Center
-
Sherman, Texas, Spojené státy, 75092
- Texas Institute for Neurological Disorders
-
Temple, Texas, Spojené státy, 76508
- Baylor Scott and White
-
-
Washington
-
Seattle, Washington, Spojené státy, 98101
- Virginia Mason Medical Centre
-
Seattle, Washington, Spojené státy, 98133
- University of Washington MS Clinic
-
-
West Virginia
-
Crab Orchard, West Virginia, Spojené státy, 25827
- Elligo Health Research
-
-
Wisconsin
-
Milwaukee, Wisconsin, Spojené státy, 53226
- Medical College of Wisconsin
-
Milwaukee, Wisconsin, Spojené státy, 53215
- Ascension St Francis Center
-
-
-
-
-
Konya, Turecko (Türkiye), 42130
- Novartis Investigative Site
-
-
Atakum
-
Samsun, Atakum, Turecko (Türkiye), 55200
- Novartis Investigative Site
-
-
Balcova
-
Izmir, Balcova, Turecko (Türkiye), 35340
- Novartis Investigative Site
-
-
Fatih
-
Istanbul, Fatih, Turecko (Türkiye), 34098
- Novartis Investigative Site
-
Istanbul, Fatih, Turecko (Türkiye), 34093
- Novartis Investigative Site
-
-
Karabaglar
-
Izmir, Karabaglar, Turecko (Türkiye), 35150
- Novartis Investigative Site
-
-
Kocaeli
-
Köseköy, Kocaeli, Turecko (Türkiye), 41380
- Novartis Investigative Site
-
-
Melikgazi
-
Kayseri, Melikgazi, Turecko (Türkiye), 38039
- Novartis Investigative Site
-
-
Nilufer
-
Bursa, Nilufer, Turecko (Türkiye), 16140
- Novartis Investigative Site
-
-
Pendik
-
Istanbul, Pendik, Turecko (Türkiye), 34899
- Novartis Investigative Site
-
-
Sancaktepe
-
Istanbul, Sancaktepe, Turecko (Türkiye), 34785
- Novartis Investigative Site
-
-
-
-
-
Brno, Česko, 602 00
- Novartis Investigative Site
-
Hradec Králové, Česko, 500 05
- Novartis Investigative Site
-
Teplice, Česko, 415 29
- Novartis Investigative Site
-
-
-
-
-
Beijing, Čína, 100034
- Novartis Investigative Site
-
Shanghai, Čína, 200025
- Novartis Investigative Site
-
Shanghai, Čína, 200040
- Novartis Investigative Site
-
-
Hubei
-
Wuhan, Hubei, Čína, 430030
- Novartis Investigative Site
-
Wuhan, Hubei, Čína, 430060
- Novartis Investigative Site
-
-
Jiangsu
-
Nanjing, Jiangsu, Čína, 210029
- Novartis Investigative Site
-
-
Ningxia
-
Yinchuan, Ningxia, Čína, 750004
- Novartis Investigative Site
-
-
Shanxi
-
Taiyuan, Shanxi, Čína, 030001
- Novartis Investigative Site
-
-
Zhejiang
-
Hangzhou, Zhejiang, Čína, 310016
- Novartis Investigative Site
-
Hangzhou, Zhejiang, Čína, 310006
- Novartis Investigative Site
-
Wenzhou, Zhejiang, Čína, 325000
- Novartis Investigative Site
-
-
-
-
-
Athens, Řecko, 115 28
- Novartis Investigative Site
-
Athens, Řecko, 115 26
- Novartis Investigative Site
-
Chaïdári, Řecko, 124 62
- Novartis Investigative Site
-
Ioannina, Řecko, 455 00
- Novartis Investigative Site
-
Larissa, Řecko, 411 10
- Novartis Investigative Site
-
Thessaloniki, Řecko, 532 46
- Novartis Investigative Site
-
Thessaloniki, Řecko, 546 36
- Novartis Investigative Site
-
-
-
-
-
Lleida, Španělsko, 25198
- Novartis Investigative Site
-
Madrid, Španělsko, 28040
- Novartis Investigative Site
-
Madrid, Španělsko, 28009
- Novartis Investigative Site
-
Málaga, Španělsko, 29016
- Novartis Investigative Site
-
Seville, Španělsko, 41009
- Novartis Investigative Site
-
Valencia, Španělsko, 46026
- Novartis Investigative Site
-
-
A Coruna
-
Santiago Compostela, A Coruna, Španělsko, 15706
- Novartis Investigative Site
-
-
Araba
-
Vitoria-Gasteiz, Araba, Španělsko, 01009
- Novartis Investigative Site
-
-
Barcelona
-
L'Hospitalet de Llobregat, Barcelona, Španělsko, 08907
- Novartis Investigative Site
-
-
Castille-La Mancha
-
Albacete, Castille-La Mancha, Španělsko, 02006
- Novartis Investigative Site
-
-
Catalonia
-
Barcelona, Catalonia, Španělsko, 08003
- Novartis Investigative Site
-
-
La Rioja
-
Logroño, La Rioja, Španělsko, 26006
- Novartis Investigative Site
-
-
Madrid
-
Pozuelo de Alarcón, Madrid, Španělsko, 28223
- Novartis Investigative Site
-
Torrejón de Ardoz, Madrid, Španělsko, 28850
- Novartis Investigative Site
-
-
Principality of Asturias
-
Gijón, Principality of Asturias, Španělsko, 33394
- Novartis Investigative Site
-
-
Valencia
-
Valencia, Valencia, Španělsko, 46017
- Novartis Investigative Site
-
-
-
-
-
Stockholm, Švédsko, 102 35
- Novartis Investigative Site
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- 18 to 55 years of age
- Diagnosis of RMS according to the 2017 McDonald diagnostic criteria
- At least: 1 documented relapse within the previous year. OR 2 documented relapses within the previous 2 years, OR 1 active Gadolinium (Gd)-enhancing lesion in the 12 months.
- EDSS score of 0 to 5.5 (inclusive)
- Neurologically stable within 1 month
Exclusion Criteria:
-
Diagnosis of primary progressive multiple sclerosis (PPMS)
-
Disease duration of more than 10 years in participants with EDSS score of 2 or less at screening
-
History of clinically significant CNS disease other than MS
-
Ongoing substance abuse (drug or alcohol)
-
History of malignancy of any organ system (other than complete resection of localized basal cell carcinoma of the skin or in situ cervical cancer),
-
Participants with history of confirmed Progressive Multifocal Leukoencephalopathy (PML) or Neurological symptoms consistent with PML
-
suicidal ideation or behavior
-
Evidence of clinically significant cardiovascular, neurological, psychiatric, pulmonary , renal, hepatic, endocrine, metabolic, hematological disorders or gastrointestinal disease that can interfere with interpretation of the study results or protocol adherence
-
Participants who have had a splenectomy
-
Active clinically significant systemic bacterial, viral, parasitic or fungal infections
-
Positive results for syphilis or tuberculosis testing
-
Uncontrolled disease states, such as asthma, or inflammatory bowel disease, where flares are commonly treated with oral or parenteral corticosteroids
-
Active, chronic disease of the immune system (including stable disease treated with immune therapy (e.g. Leflunomide, Methotrexate)) other than MS (e.g. rheumatoid arthritis, systemic lupus erythematosus, etc.) with the exception of well-controlled diabetes or thyroid disorder.
-
Participants with a known immunodeficiency syndrome (AIDS, hereditary immune deficiency, drug induced immune deficiency), or tested positive for HIV antibody
-
History or current treatment for hepatic disease including but not limited to acute or chronic hepatitis, cirrhosis (including all Child-Pugh classes) or hepatic failure or any chronic liver or biliary disease.
-
History of severe renal disease or creatinine level
-
Participants at risk of developing or having reactivation of hepatitis
-
Hematology parameters at screening:
- Hemoglobin: < 10 g/dl (<100g/L)
- Platelets: < 100000/mm3 (<100 x 109/L)
- Absolute lymphocyte count < 800/mm3 (<0.8 x 109/L)
- White blood cells: <3 000/mm3 (<3.0 x 109/L)
- Neutrophils: < 1 500/mm3 (<1.5 x 109/L)
- B-cell count < 50% lower limit of normal (LLN) or total IgG & total IgM < LLN (only required for participants who had a history of receiving B-cell therapies, such as rituximab, ocrelizumab or ofatumumab, prior to screening)
-
History or current diagnosis of significant ECG abnormalities
-
Resting QTcF ≥450 msec (male) or ≥460 msec (female) at pre-treatment as per central ECG reading at screening visit
-
Use of other investigational drugs
-
Requirement for anticoagulant medication or use of dual anti-platelet therapy Significant bleeding risk or coagulation disorders,
-
History of gastrointestinal bleeding
-
Major surgery within 8 weeks prior to screening
-
History of hypersensitivity to any of the study drugs or excipients
-
Pregnant or nursing (lactating) female participants, prior to randomization
-
Women of childbearing potential not using highly effective contraception
-
Sexually active males not agreeing to use condom
-
Have received any live or live-attenuated vaccines within 6 weeks of randomization or requirement to receive these vaccinations during study
-
Use of strong CYP3A4 inhibitors or use of moderate or strong CYP3A4 inducers within two weeks prior to randomization
Inclusion to Extension part:
• Participants who complete the Core Part of the study on double-blind study treatment and conduct the Accelerated Elimination Procedure (AEP)
Other inclusion and exclusion criteria may apply.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Dvojnásobek
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: Remibrutinib - Core
Remibrutinib tablet and matching placebo of teriflunomide capsule |
tablet taken orally
Ostatní jména:
|
|
Aktivní komparátor: Teriflunomide - Core
Teriflunomide capsule and matching placebo remibrutinib tablet |
capsule taken orally |
|
Experimentální: Remibrutinib - Extension
Participants on remibrutinib in Core will continue on remibrutinib tablet |
tablet taken orally
Ostatní jména:
|
|
Experimentální: Remibrutinib - Extension (on teriflunomide in Core)
Participants on teriflunomide in Core will switch to remibrutinib tablet |
tablet taken orally
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Annualized relapse rate (ARR) of confirmed relapses [Core Part]
Časové okno: From Baseline, up to 30 months
|
ARR is the average number of confirmed MS relapses in a year |
From Baseline, up to 30 months
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Time to 3-month confirmed disability progression (3mCDP) on Expanded Disability Status Scale (EDSS) [Core Part] (pooled data)
Časové okno: Baseline up to 30 months
|
Time to 3-month confirmed disability progression (3mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 3 months |
Baseline up to 30 months
|
|
Time to 6-month confirmed disability progression (6mCDP) on EDSS [Core Part] (pooled data)
Časové okno: Baseline up to 30 months
|
Time to 6-month confirmed disability progression (6mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 6 months |
Baseline up to 30 months
|
|
Annualized rate of new or enlarging T2 lesion [Core Part]
Časové okno: Baseline up to 30 months
|
Number of new/newly enlarged T2 lesions per year |
Baseline up to 30 months
|
|
Neurofilament light chain (Nfl) [Core Part]
Časové okno: Baseline up to 30 months
|
Neurofilament light chain (NfL) concentration in serum |
Baseline up to 30 months
|
|
Number of Gd-enhancing T1 lesions per MRI scan [Core Part]
Časové okno: Baseline up to 30 months
|
Average number of Gd-enhancing T1 lesions per scan |
Baseline up to 30 months
|
|
Percentage of participants with No Evidence of Disease Activity-3 (NEDA-3) [Core Part] (pooled data)
Časové okno: Baseline up to 30 months
|
Percentage of participants with No Evidence of Disease Activity-3 (NEDA-3), as assessed by absence of confirmed MS relapses, 6mCDP and new/enlarging T2 lesions on MRI |
Baseline up to 30 months
|
|
Time to first confirmed relapse [Core Part]
Časové okno: Baseline up to 30 months
|
Change in the Expanded Disability Status Scale (EDSS), an increase of at least 0.5 points on the EDSS (total) score, or an increase of at least 1 point on at least two functional scores (FSs), or an increase of at least 2 points on at least one FS, excluding changes involving bowel/bladder or cerebral FS, compared to the previous available rating. |
Baseline up to 30 months
|
|
Time to 6-month confirmed disability improvement (6mCDI) on EDSS [Core Part] (pooled data)
Časové okno: Baseline up to 30 months
|
Decrease in Expanded Disability Status Scale Score (EDSS) which is sustained for at least 6 months |
Baseline up to 30 months
|
|
Time to 3-months confirmed disability progression (3mCDP) and 6-month confirmed disability progression (6mCDP) independent of relapse activity (PIRA) [Core Part] (pooled data)
Časové okno: Baseline up to 30 months
|
Time to 3-month confirmed disability progression (3mCDP) and 6-month confirmed disability progression (6mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 3 months or 6 months, respectively, without an on-study relapse before or on the day of a progression eve |
Baseline up to 30 months
|
|
Change from baseline in the Symbol Digit Modalities Test (SDMT) [Core Part] (pooled data)
Časové okno: Baseline up to 30 months
|
Symbol Digit Modalities Test (SDMT), an array of symbols paired with empty spaces, measures processing in speed; participants verbally match the number for each symbol as rapidly as possible. The score is the number of correctly coded items in 90 seconds. Higher scores indicate improvement. Lower scores indicate worsening |
Baseline up to 30 months
|
|
Time to 6-month confirmed worsening by at least 20% in the Timed 25-foot walk test (T25FW) [Core Part] (pooled data)
Časové okno: Baseline, up to 30 months
|
The patient walking speed to cover 25-foot distance is recorded in seconds. Longer time indicates poorer lower limb function. 20% worsening is defined as 20% increase from baseline T25FW score |
Baseline, up to 30 months
|
|
Time to 6-month confirmed worsening by at least 20% in the Timed 9-hole peg test (9HPT) (pooled data) [Core Part] (pooled data)
Časové okno: Baseline up to 30 months
|
The patient's right and left arm function to peg 9 holes measured in seconds. Longer time indicates poorer upper limb function. 20% worsening is defined as 20% increase from baseline 9HPT score in at least one hand (average of two trials per hand) |
Baseline up to 30 months
|
|
Time to composite 6-month confirmed disability Progression (CDP) [Core Part] (pooled data)
Časové okno: Baseline up to 30 months
|
The composite involves CDP and worsening by at least 20% in T25FW and 9HPT |
Baseline up to 30 months
|
|
Change from Baseline in T2 lesion volume [Core Part]
Časové okno: Baseline up to 30 months
|
Change from baseline in total T2 lesion volume. |
Baseline up to 30 months
|
|
Change from baseline in Multiple Sclerosis Impact Scale (MSIS-29) [Core Part]
Časové okno: Baseline up to 30 months
|
29-item, self-administered questionnaire that includes 2 domains, physical and psychological. Responses are captured on a 4-point scale ranging from "not at all" (1) to "extremely" (4), where higher scores reflect greater impact on day to day life |
Baseline up to 30 months
|
|
Number of participants with Adverse events and Serious adverse events(SAE) [Core Part]
Časové okno: Baseline up to 30 months
|
Adverse events and SAEs including clinically significant, laboratory data, vital signs, electrocardiogram (ECG), Columbia Suicide Severity Rating |
Baseline up to 30 months
|
|
Pharmacokinetics of remibrutinib [Core Part]
Časové okno: Month 1, Month 6
|
Blood concentrations of remibrutinib |
Month 1, Month 6
|
|
Number of participants with Adverse events and Serious adverse events (SAE) [Extension Part]
Časové okno: Day 1 Extension up to 5 years
|
Adverse events and SAEs including clinically significant, laboratory data, vital signs, electrocardiogram (ECG), Columbia Suicide Severity Rating |
Day 1 Extension up to 5 years
|
|
Annualized relapse rate (ARR) of confirmed relapses [Extension Part]
Časové okno: Day 1 Extension up to 5 years
|
ARR is the average number of confirmed MS relapses in a year |
Day 1 Extension up to 5 years
|
|
Annualized rate of new or enlarging T2 lesion [Extension Part]
Časové okno: Day 1 Extension up to 5 years
|
Number of new/newly enlarged T2 lesions per year |
Day 1 Extension up to 5 years
|
|
Time to 6-month confirmed disability progression (6mCDP) on EDSS [Extension Part]
Časové okno: Day 1 Extension up to 5 years
|
Time to 6-month confirmed disability progression (6mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 6 months |
Day 1 Extension up to 5 years
|
|
Change from baseline in the Symbol Digit Modalities Test (SDMT) [Extension Part]
Časové okno: Day 1 Extension up to 5 years
|
Symbol Digit Modalities Test (SDMT), an array of symbols paired with empty spaces, measures processing in speed; participants verbally match the number for each symbol as rapidly as possible. The score is the number of correctly coded items in 90 seconds. Higher scores indicate improvement. Lower scores indicate worsening |
Day 1 Extension up to 5 years
|
|
Neurofilament light chain (NfL) [Extension Part]
Časové okno: Day 1 Extension up to 5 years
|
Neurofilament light chain (NfL) concentration in serum |
Day 1 Extension up to 5 years
|
|
Change from baseline in Multiple Sclerosis Impact Scale (MSIS-29) [Extension Part]
Časové okno: Day 1 Extension up to 5 years
|
29-item, self-administered questionnaire that includes 2 domains, physical and psychological. Responses are captured on a 4-point scale ranging from "not at all" (1) to "extremely" (4), where higher scores reflect greater impact on day to day life |
Day 1 Extension up to 5 years
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Vyšetřovatelé
Vyšetřovatelé
- Ředitel studie: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Aktuální)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- CLOU064C12302
- 2023-509372-41-00 (Identifikátor registru: EU CTIS)
- 2023 (Grant/smlouva NIH USA)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .